Vanda puts anxiety drug program on hold after Phase III setback

Phase 3negativeNegative

AI Analysis

Summary

Vanda Pharmaceuticals has halted its anxiety drug program following a Phase III trial setback. The negative trial outcome has resulted in the company putting the development program on hold.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Phase III setback led to program being put on hold

Importance:7/10

Sentiment:

-0.80

clinical trial failureprogram holdanxiety treatmentPhase 3

Related Companies

$VNDA

Read the original article

Published by Seeking Alpha Healthcare on October 15, 2026 10:15 AM

Read Original